FDA Proposes to Exclude GLP 1s From 503B Bulk List Drug Topics Navigating the FDA's Final Interim Policy on Compounding with Bulk Drug Substances: A Guide for 503A Pharmacies and 503B Outsourcing Facilities Buchanan Ingersoll & Rooney PC BULK DRUG SUBSTANCES AND FDA EVALUATION The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them Is BPC 157 Banned? Oral vs. Injectable Forms Explained